Incredibly proud of my mentee Mohamad El-Jammal from @AUB_Lebanon @AUB_FM for earning a well deserved residency match @StanfordRadOnc #Match2026 #RadOnc #investinscience #notwars

share.google/MMRiMZ3Od6vXoK1… China spends $786B on R&D. The US spends $782B. Even Germany, South Korea and Japan invest aggressively in innovation. India? $76B. @narendramodi ji, how exactly do you plan to build Viksit Bharat 2047 without investing in research, science, and innovation today? You can’t PowerPoint your way to global leadership. No nation becomes developed by slogans, only by sustained investment in knowledge, labs, universities, and talent. 2047 needs R&D now, not speeches about the future. #ViksitBharat2047 #InvestInScience #RAndDMatters #KnowledgeEconomy #DataSpeaks

A ten-year science and innovation strategy for Africa from 2025 to 2034 is anticipated to cost US$6.8 billion to implement. researchprofessionalnews.com… #InvestinScience #AfricanScience

❓ Did you know? Every $1 invested in CGIAR research returns $10 in impact. With new funding announced at #COP30, we’re scaling solutions for food, land, and water systems. on.cgiar.org/49VixIl #InvestInScience #COP30 #FoodSystems

Join eDMT – Turn Crypto Into Real-World Science 💎 @BioProtocol With $eDMT, the community funds, governs, and benefits from cutting - edge research. Stake tokens to earn BioXP, contribute to real scientific breakthroughs, and enjoy a fair share of results through its Commons IP model. Don’t just trade - invest in science, impact, and the future. eDMT makes you a shareholder in the world’s next DeSci revolution! #eDMT #InvestInScience #DeSciRevolution #BioProtocol #BioXP #BlockchainScience #CryptoInnovation #CommonsIP

🌍 Healing PTSD isn’t just about medicine — it’s about building community power and shared ownership. Spectruth DAO’s governance model empowers members to steer research and share in innovation value. Be part of a global movement changing mental health care forever. #DAOCommunity #HealingTogether #InvestInScience #DeSciRevolution

The first two projects launched on BioProtocol’s platform made a huge splash: BiomeAI $BiomeAI was oversubscribed by 6.4x, while eDMT $eDMT reached 4.2x. These numbers the massive demand for capital flowing into DeSci (Decentralized Science) where science meets blockchain. Such strong oversubscription shows that investor demand far exceeds supply, setting the stage for explosive growth post-TGE. What stands out is that every project is tied to $BIO, creating a cycle of value: users stake and hold $BIO to participate, new projects attract capital back into the ecosystem, demand rises, and $BIO’s central role is reinforced. Unlike pure DeFi, DeSci introduces a game-changing mechanism: tokenized scientific IP. By investing in eDMT, investors gain rights linked to research on natural DMT in the brain. If this research reaches medical or commercial application, the IP value will rise and be directly reflected in the token. This creates a tangible bridge between scientific research and financial returns something traditional markets could rarely achieve. Most importantly, DeSci offers a sustainable path: generating profits for investors while carrying a strong social impact. This dual nature positions it to attract not only the crypto community but also capital from ESG, health-tech, and biotech funds worldwide. 🔥 BioProtocol is proving that science can be transformed into an on-chain investment asset. With massive oversubscriptions from the very first launches, DeSci is no longer a distant concept it’s shaping up to be the next big wave in Web3. @BioProtocol @BiomeAI @edmtcomms #DeSci #BioProtocol #CryptoHealth #InvestInScience #DAO

🎉 Huge congrats to @BioProtocol for their 2 successful launches yesterday! 🚀 Special shoutout to @BiomeAI ( $BiomeAI ) — launching BioAgent for personalized microbiome health & trials 🧬💡 And @edmtcomms ( $eDMT ) — debuting the IP Token exploring natural DMT production in the brain 🌱✨ We’re proud to join the launchpad with our @spectra_agentic ($SPAI) for PTSD health & trials and @Ai_Nightingale ($NGHT) for live PTSD data collection and therapy generation — all powered on $BIO within the @BioProtocolEco system. 🔗 Together, building the decentralized science ecosystem transforming mental health & biotech investing. 🔥 #DeSci #DAO #CryptoHealth #TokenizedIP #BioProtocol #InvestInScience

🧬 The $NWBO Immune OS Was Already Tested: How #DCVax, RevImmune, and CYT107 Quietly Rewrote Survival in Pediatric Sarcomas 📍ClinicalTrials.gov: NCT00923351 This was not experimental guesswork. This was the DCVax method fully implemented, 8 years ago, in pediatric sarcomas. Led by Crystal Mackall at the NIH, the trial enrolled 43 patients with metastatic or recurrent Ewing sarcoma, rhabdomyosarcoma, and related high-risk tumors. The immune platform was: ✔️ Tumor lysate from patient biopsy ✔️ Autologous dendritic cells, matured ex vivo ✔️ CD25⁺ Treg-depleted lymphocyte reinfusion ✔️ 6 rounds of vaccination over 10 weeks ✔️ Recombinant IL-7 (CYT107) in Arm B to boost immune recovery ✔️ Cryopreserved tracking and DTH skin testing ✔️ Fully GMP-compatible This was not a checkpoint inhibitor trial. It was programmable immunotherapy, before the name existed. 📈 Here’s What Happened: ✅ 100% of patients in the vaccine arm mounted a KLH-specific immune response ✅ 62% developed confirmed tumor-specific T-cell responses (ex vivo IFN-γ assay) ✅ Arm B (with IL-7): 57.7% showed positive DTH responses to tumor lysate ✅ 5 of 5 DTH-negative patients were in Arm A (no IL-7) The immune response was real. And it tracked with survival. 🧬 Survival Data NCT00923351 🎯 Newly Diagnosed Metastatic Ewing/RMS • 5-Year Overall Survival (Intent-to-Treat): 83.3% • Prior-generation cohort: 25% • P = 0.017 when tumor-specific immune response was detected • Median OS (Arm B): 4.3 years (range: 0.9 to 10.4 years) • 6 of 6 patients in Arm A survived (100%), though fewer mounted measurable responses 🧪 One patient with over 100 lung metastases remains alive, cancer-free, 7 years later. “I’d like to see more cancer therapies that apply to stage four metastatic disease… therapies that result in a complete pathologic response, that is, the cancer melts away, without chemo, surgery, or radiation.” Dr. Marty Makary, FDA Commissioner 🔗 CYT107 Was Not Just a Cytokine. It Was a Strategic Asset. IL-7 (CYT107) wasn’t a throw-in. It was the terrain calibrator. And it is owned by RevImmune. RevImmune is directed by Linda Powers, who is also the CEO of Northwest Biotherapeutics ($NWBO). This means both the instruction layer (DCVax) and the immune recovery booster (IL-7) were under unified ownership, years before the public understood the stack. ⚙️ The Platform Was Already Fully Aligned: • Instruction: Autologous tumor antigens • Compiler: Flaskworks Eden (now GMP-automated) • Booster: CYT107 terrain recovery (IL-7) • Execution Sites: Advent (UK), Winterfell (US), C3i (Canada) • Traceability: GMP, cryogenic recall, automated QC • Ownership: Linda Powers across instruction and booster class This is not a speculative system. It was executed once. The results are public. The infrastructure is now global. 🧠 Strategic Takeaway This wasn’t an isolated study. It was a real-world execution of programmable dendritic cell immunotherapy across multiple tumor types, with durable survival and 100% immune engagement in KLH assays. If the tumor is readable, the platform works. If terrain is supported with IL-7, the immune system responds. If cryogenic traceability is in place, the network can deploy globally. The architecture is modular. The signal has been validated. The system is already online. 📜 Disclaimer This is not investment advice or a regulatory claim. Clinical data is sourced directly from ClinicalTrials.gov and the official NCI submission for NCT00923351. All survival and immune response metrics are publicly reported. CYT107 is the property of RevImmune. Flaskworks Eden is a GMP automation platform developed for NWBO. Interpretations reflect the convergence of publicly disclosed infrastructure, ownership, and validated immunologic method. #Immunotherapy #DCVax #DendriticCells #CancerResearch #BiotechStocks #NWBO #RevImmune #CYT107 #CellTherapy #ClinicalTrials #CancerSurvivorship #ImmuneOS #OncologyInnovation #PrecisionMedicine #PediatricCancer #PlatformBiotech #ImmunoEngineering #NIH #TCellTherapy #InvestInScience

Africa’s scientific future depends on sustained local investment. Let’s prioritize homegrown research to drive innovation and safeguard progress. Proud to see @WACCBIP_UG leading the charge at the 9th Conference at UG! 🔬🌍 #WACCBIP2025 #InvestInScience

Anxiety helps us stay alert, but too much can interfere with daily life. @DemaestriC studies how trauma and stress can change the brain and make anxiety spiral out of control. #anxiety #stress #chronicstress #trauma #amygdala #behvavioralneuroscience #investinscience

👉holoharmoniq.com/collab #HoloHarmoniq #HealthTech #Neurotech #DeepTech #FutureOfWellbeing #AI #InvestInScience

Dreaming of accelerating life-saving science? Etica empowers you to fund research that changes the world. Join our DAO & shape the future! 🔬x.com/eticaprotocol #DeSci #DAO #InvestInScience

Billions live with HSV-1 or HSV-2. Still no cure. Still no vaccine. Still underfunded. We need research, now. @NIH @HHSGov @CDCSTD @NIAIDNews #CureHerpes #InvestInScience #HSV

Healing Anxiety from the Inside Out: @MelanieOrtizAl1 discusses the gut-brain connection and how their research informs anxiety treatments #science #research #scicomm #anxiety #scienceForSociety #investInScience #investNscience

Why does addiction affect some people but not others? @brenna_williams studies how experiences and genetics underlie addiction to help develop personalized treatments. #Neuroscience #addiction #epigenetics #personalizedtreatments #investinscience

During her visit to London in December, Krystal Birungi @XtalBirungi of #TargetMalariaUganda @UVRIug highlighted the urgent need for increased investment in malaria research and intervention. Together, we can drive innovation, strengthen efforts, and move closer to a #malaria-free world. 🌍🦟 Read more about her advocacy here in this article by Julius Nwemba at News Excavators: newsexcavator.com/birungi-ad… #EndMalaria #InvestInScience #MalariaFreeFuture #GlobalHealth

Invest in the Future of Science! 🌍 DeSciAi is revolutionizing research funding—giving investors, researchers & society a stake in groundbreaking discoveries. 🔗Read More link.medium.com/bzTrfcEGUQb Back innovation early, shape the future, and earn from scientific breakthroughs!🧑‍🔬 #DeSci #InvestInScience #DeSciAi

Indirect costs cover lab space, research personnel, n equipment maintenance—essentials that keep scientific discoveries moving forward. Slashing these funds means fewer experiments, fewer breakthroughs, and, ultimately, fewer lives saved. @doge #InvestInScience #RareDiseaseTruth

Investing in research and development (R&D) is the cornerstone of advancing nations and institutions. The 2023 World Bank report revealed that every dollar invested in scientific research generates an economic return of $2.5 to $4.0. For example, South Korea allocates 4.8% of its GDP to R&D, positioning it as a global leader in innovation. #InvestInScience #SustainableDevelopment